

MAR. 20. 2006 1:13PM



BMS PATENT DEPT

Bristol-Myers Squibb Company

Worldwide Medicines Group
P.O. Box 4000 Princeton, NJ 08543-4000

NO. 9969 P. 1

**RECEIVED
CENTRAL FAX CENTER**

MAR 20 2006

DATE: March 20, 2006

FACSIMILE TRANSMITTAL COVER SHEET

URGENT

TO: USPTO
FAX: 1-571-273-8300
OF PAGES: 9 (INCLUDING FAX TRANSMITTAL SHEET)
FROM: Stephen C. D'Amico
FAX #: (609) 252-4526
PHONE #: (609) 252-5289
RE: U.S. Appln. Serial No.: 10/635,977
Attorney Docket No. D0283A CIP

Comments: Please see attached:
1) Response to Restrict Requirement Without Traverse
2) Preliminary Amendment attaching (ATCC Deposit)

Should you not receive all six (9) pages of this facsimile, please contact Joyce Whitlow at 609-252-3597

THE INFORMATION CONTAINED IN THIS FAX MESSAGE IS INTENDED ONLY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE RECIPIENT(S) NAMED ABOVE. THIS MESSAGE MAY BE AN ATTORNEY-CLIENT COMMUNICATION AND AS SUCH IS PRIVILEGED AND CONFIDENTIAL. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR AN AGENT RESPONSIBLE FOR DELIVERING TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR AND THAT ANY REVIEW, DISSEMINATION, DISTRIBUTION, OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.

MAR. 20. 2006 1:13PM

BMS PATENT DEPT

RECEIVED
CENTRAL FAX CENTER

MAR 20 2006

NO. 9969 P. 2
CASE D0283A CIP

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being facsimile transmitted to the Patent and Trademark Office (571-273-8300) on the date shown below.

Stephen C. D'Amico
Type or print name


Signature

March 20, 2006
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1653

FEDER ET AL.

Examiner: MONSHIPOURI, MARYAM

APPLICATION NO: 10/635,977

FILED: AUGUST 7, 2003

FOR: POLYNUCLEOTIDES ENCODING A NOVEL TESTIS-SPECIFIC

TUBULIN TYROSINE-LIGASE-LIKE PROTEIN, BGS42

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**RESPONSE TO RESTRICTION REQUIREMENT
WITHOUT TRAVERSE**

Sir:

In reply to the Office Action dated January 7, 2005, requesting an election of one invention to prosecute in the above-referenced patent application, Applicants hereby provisionally elect to prosecute the invention of Group II, without traverse, drawn to an isolated tyrosine ligase-like polypeptide (BGS-42). This election is made without prejudice to or disclaimer of the other claims or inventions disclosed.


A three-month extension is hereby requested pursuant to 37 CFR §1.136(a). Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$1020 for payment of the extension fee.

- 1 -

If any fee is due in connection herewith, please charge such fee to Deposit Account No. 19-3880 of the undersigned. Furthermore, if any extension of time not already accounted for is required, such extension is hereby petitioned for, and it is requested that any fee due for said extension be charged to the above-stated Deposit Account.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5289
Date: March 20, 2006


Stephen C. D'Amico
Agent for Applicants
Reg. No. 46,652